|
gptkbp:instanceOf
|
gptkb:synthetic_cannabinoid
|
|
gptkbp:actsOn
|
gptkb:CB1_receptor
gptkb:CB2_receptor
|
|
gptkbp:alsoKnownAs
|
5F-MDMB-PINACA
|
|
gptkbp:bannedIn
|
gptkb:Australia
gptkb:China
gptkb:Denmark
gptkb:Estonia
gptkb:Finland
gptkb:France
gptkb:Germany
gptkb:Italy
gptkb:Japan
gptkb:Latvia
gptkb:Lithuania
gptkb:New_Zealand
gptkb:Norway
gptkb:Poland
gptkb:Russia
gptkb:Singapore
gptkb:South_Korea
gptkb:Sweden
gptkb:Turkey
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:category
|
indazole-based synthetic cannabinoid
|
|
gptkbp:chemicalFormula
|
C20H28FN3O3
|
|
gptkbp:detects
|
forensic toxicology cases
|
|
gptkbp:discoveredBy
|
gptkb:Japan
|
|
gptkbp:discoveredIn
|
2014
|
|
gptkbp:IUPACName
|
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
|
|
gptkbp:legalStatus
|
gptkb:Schedule_II_(Canada)
gptkb:Schedule_I_(United_States)
NpSG (Germany)
Class B (United Kingdom)
|
|
gptkbp:marketedAs
|
gptkb:spice
herbal incense
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
377.46 g/mol
|
|
gptkbp:relatedTo
|
gptkb:5F-AB-PINACA
MDMB-FUBINACA
ADB-FUBINACA
|
|
gptkbp:routeOfAdministration
|
smoking
oral
inhalation
|
|
gptkbp:sideEffect
|
gptkb:death
seizures
tachycardia
agitation
|
|
gptkbp:toxicity
|
high
|
|
gptkbp:usedAs
|
gptkb:recreational_drug
|
|
gptkbp:bfsParent
|
gptkb:5F6-A
gptkb:MAU-209
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
5F-ADB
|